BiomX’s (PHGE) Buy Rating Reaffirmed at HC Wainwright

HC Wainwright reissued their buy rating on shares of BiomX (NYSEMKT:PHGE) in a research note published on Friday morning,Benzinga reports. HC Wainwright currently has a $21.00 price objective on the stock. HC Wainwright also issued estimates for BiomX’s Q1 2025 earnings at ($0.42) EPS, Q2 2025 earnings at ($0.46) EPS, Q3 2025 earnings at ($0.49) EPS, Q4 2025 earnings at ($0.53) EPS, FY2025 earnings at ($1.90) EPS, FY2026 earnings at ($1.86) EPS, FY2027 earnings at ($2.08) EPS and FY2028 earnings at ($1.84) EPS.

BiomX Stock Performance

The company has a quick ratio of 2.84, a current ratio of 2.84 and a debt-to-equity ratio of 0.51. The firm’s 50-day simple moving average is $0.71 and its 200 day simple moving average is $0.75. BiomX has a 1-year low of $0.48 and a 1-year high of $4.99. The stock has a market capitalization of $13.89 million, a price-to-earnings ratio of -0.76 and a beta of 1.38.

Institutional Investors Weigh In On BiomX

A number of institutional investors have recently made changes to their positions in PHGE. Alyeska Investment Group L.P. bought a new position in BiomX in the 4th quarter valued at approximately $632,000. Allostery Investments LP purchased a new stake in shares of BiomX during the fourth quarter valued at $470,000. Finally, JPMorgan Chase & Co. purchased a new stake in shares of BiomX during the fourth quarter valued at $314,000. Hedge funds and other institutional investors own 40.57% of the company’s stock.

About BiomX

BiomX Inc, a clinical-stage biopharmaceutical company, develops products using natural and engineered phage technologies designed to target and kill specific harmful bacteria associated with chronic disease. It is developing BX211, a phage therapy, which is in phase 2 clinical study for the treatment of diabetic foot osteomyelitis.